PureTech Health (GB:PRTC) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
PureTech Health plc has announced the FDA approval of their groundbreaking schizophrenia treatment, KarXT, now branded as Cobenfy, marking a significant innovation in neuropsychiatric medicine. The approval has resulted in milestone payments of $29 million to PureTech, with further potential payments and royalties on substantial net sales. The success of Cobenfy, the first major therapeutic advance in over 50 years, underlines PureTech’s unique R&D model and financial strategy, allowing the company to self-fund further drug development programs.
For further insights into GB:PRTC stock, check out TipRanks’ Stock Analysis page.
